scispace - formally typeset
C

Carlo Pellegrini

Researcher at University of Pavia

Publications -  61
Citations -  2159

Carlo Pellegrini is an academic researcher from University of Pavia. The author has contributed to research in topics: Transplantation & Heart transplantation. The author has an hindex of 21, co-authored 53 publications receiving 1813 citations. Previous affiliations of Carlo Pellegrini include Foundation University, Islamabad.

Papers
More filters
Journal ArticleDOI

Myocardial localization of coronavirus in COVID-19 cardiogenic shock.

TL;DR: This is the first case of acute cardiac injury directly linked to myocardial localization of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in a 69‐year‐old patient with flu‐like symptoms rapidly degenerating into respiratory distress, hypotension, and cardiogenic shock.
Journal ArticleDOI

Monitoring of Human Cytomegalovirus‐Specific CD4+ and CD8+ T‐Cell Immunity in Patients Receiving Solid Organ Transplantation

TL;DR: The number of HCMV‐specific CD4+ and CD8+ T‐cells detected prior to transplantation significantly correlated with time to T‐cell immunity restoration, in that higher HCMv‐specific T‐ cell counts predicted earlier immune restoration.
Journal ArticleDOI

Desmin accumulation restrictive cardiomyopathy and atrioventricular block associated with desmin gene defects.

TL;DR: Primary desminopathies are caused by desmin gene [DES (MIM*125660)] mutations and the clinical spectrum includes pure myopathies, cardiomuscular diseases and cardiomyopathies.
Journal ArticleDOI

Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients.

TL;DR: About 50% of respiratory tract infections of lung transplant recipients were associated with one or more respiratory viruses, and a high HCMV load in bronchoalveolar lavage is a risk factor for viral pneumonia, suggesting some measure of intervention for the control of viral infection.
Journal ArticleDOI

Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation.

TL;DR: Control of human cytomegalovirus infection during the posttransplant period was investigated in 134 solid‐organ transplant recipients by monitoring in parallel virologic and immunologic parameters for at least 1 year of follow‐up, and the presence of both HCMV‐specific CD4+ and CD8+ T cells ≥ 0.4/μL blood appears to be protective against H CMV disease.